Clinical trials on Rotator Cuff Tendinopathy

Rotator Cuff Tendinopathy

Rotator cuff tendinopathy involves irritation or damage to the tendons of the shoulder’s rotator cuff, leading to pain and limited movement. This condition often affects the ability to lift the arm or perform overhead activities.


  • Chronic pain and stiffness in the shoulder, which may worsen without treatment.
  • Increased risk of tendon tears or complete ruptures.
  • Decreased shoulder function, potentially impacting daily activities and quality of life.
  • Progressive weakness and muscle atrophy in the shoulder.
  • Complications affecting overall mobility and physical independence.

Treatment methods

  • Physical therapy: Focuses on exercises to strengthen shoulder muscles and improve flexibility.
  • Corticosteroid injections: Administered to reduce inflammation and alleviate pain.
  • Surgery: Considered for severe cases or when other treatments fail to provide relief.
  • NSAIDs: Commonly used to manage pain and inflammation.


With appropriate treatment, the prognosis for rotator cuff tendinopathy is generally good, with many individuals experiencing symptom relief and improved function. Without treatment, the condition may lead to chronic pain, reduced mobility, and long-term disability. Early intervention is key to preventing serious complications and achieving a positive outcome.
  • CT-EU-00117215

    Study of a new drug for moderate to severe Rotator Cuff Tendinopathy

    The clinical trial examines the use of secukinumab, a drug, for treating moderate to severe rotator cuff tendinopathy—a shoulder condition characterized by pain and limited movement. The study explores whether secukinumab can improve symptoms and physical function compared to a placebo. Participants will receive either the drug or placebo in addition to standard care, under a randomized, double-blind, and placebo-controlled setup, to ensure the results are unbiased.

    • placebo
    • Secukinumab
  • Study on Secukinumab for Rotator Cuff Tendinopathy

    This clinical trial evaluates the efficacy of the drug secukinumab in treating moderate to severe rotator cuff tendinopathy. Participants will receive secukinumab or a placebo, both in conjunction with standard care, to see if there is an improvement in symptoms and physical function. The research is conducted through a controlled setup where neither the participants nor the researchers know who receives the drug or the placebo to ensure unbiased results. This research aims to provide valuable insights into the potential benefits of secukinumab for those struggling with this shoulder condition.

    • placebo
    • Secukinumab
  • Evaluating the efficacy and safety of secukinumab in treating rotator cuff tendinopathy

    This study investigates the effectiveness and safety of a medication called AIN457, also known as secukinumab, in treating moderate to severe rotator cuff tendinopathy in adults. The study is a randomized, double-blind, placebo-controlled trial, meaning participants will either receive the active medication or a placebo without knowing which one. The treatment aims to alleviate symptoms of rotator cuff tendinopathy, a condition affecting the shoulder’s tendons, which can cause pain and limit movement.

    The study duration is 24 weeks, with a 12-week treatment period followed by 12 weeks of follow-up. During this time, participants will receive several injections of either secukinumab or a placebo. The study also involves a screening period to determine eligibility and a run-in period with standardized physiotherapy before the main treatment phase begins. The study’s primary focus is on measuring how well secukinumab relieves clinical symptoms compared to the placebo at week 24.

    • Secukinumab